31431-10-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Methylsulfanyl-2-nitroaniline is used as a chemical intermediate for the synthesis of metabolites of Albendazole (A511610). 5-Methylsulfanyl-2-nitroaniline plays a crucial role in the production of pharmaceuticals, particularly those targeting parasitic infections. Its presence in the synthesis process allows for the development of effective treatments and contributes to the advancement of medicinal chemistry.

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 5188-07-8 sodium thiomethoxide 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 5443-33-4 N-(5-chloro-2-nitrophenyl)acetamide 
• 701-57-5 1-methylthio-4-nitro-benzene 
• 857786-53-9 bis-(3-acetylamino-4-nitro-phenyl)-disulfide 

Downstream Products

• 119982-65-9 (3-chloro-4-nitrophenyl)(methyl)sulfane 
• 20901-66-0 2-chloro-4-methylthiobenzeneamine 
• 67469-02-7 4-methylsulfanylbenzene-1,2-diamine 
• 121537-61-9 6-(methylthio)-1H-benzimidazole 
• 960000-77-5 methyl 5-(5-(methylthio)-1H-benzimidazol-1-yl)-3-((phenylmethyl)oxy)-2-thiophenecarboxylate 
• 960000-79-7 methyl 5-(5-(methylsulfonyl)-1H-benzimidazol-1-yl)-3-((phenylmethyl)oxy)-2-thiophenecarboxylate 
• 121444-20-0 5-(methylsulfonyl)-2-nitroaniline 

Relevant academic research and scientific papers

Benzimidazole derivatives, their preparation and their application in medicine and pharmacology (by machine translation)

The invention relates to a new control or inhibit indocyanine 2, 3 - dioxygenase (IDO) activity of the benzimidazole derivatives, their preparation and their application in medicine and pharmacology. Specifically, the invention relates to a compound of general formula (I) compound of formula and its pharmaceutically acceptable salt, containing the compound or its pharmaceutically acceptable salt of the pharmaceutical composition, the use of the compound or its pharmaceutically acceptable salts for treating and/or preventing the relevance of the IDO-mediated disease, especially a tumor of the method and the compound or its pharmaceutically acceptable salts thereof. The invention also relates to the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition for treating and/or preventing the relevance of the IDO-mediated disease, in particular of the use of the drug in the tumor. Wherein the general formula (I) of each substituent is as defined in the specification. (by machine translation)

In Situ Formation of N-Heterocyclic Carbene-Bound Single-Molecule Junctions

Self-assembled monolayers (SAMs) formed using N-heterocyclic carbenes (NHCs) have recently emerged as thermally and chemically ultrastable alternatives to those formed from thiols. The rich chemistry and strong σ-donating ability of NHCs offer unique pros

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

NOVEL SUBSTITUTED HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Substituted heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I).

Benzimidazole Thiophene Compounds

The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

BENZIMIDAZOLE THIOPHENE COMPOUNDS

The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

A convenient copper-catalyzed direct animation of nitroarenes with 9-alkylhydroxylamines

O-Alkylhydroxylamines, particularly O-methylhydroxylamine, aminate nitroarenes in the presence of a strong base and a copper catalyst to give aminonitroarenes in good yields, ortho- or para-Animation with respect to the nitro group takes place, and in some cases the ortho-aminated product is preferentially obtained. With 3-substituted nitrobenzenes where the substituent has a lone pair of electrons, preferential amination occurs at the 2-position to give the sterically most congested 3c-f, 14 and 22g.